63876 Federal Register / Vol. 65, No. 207 / Wednesday, October 25, 2000 / Notices

structural genes (Gag/Pol and Env). Rev

is an HIV encoded protein which binds

to RRE. This interaction is essential for

nucleo-cytoplasmic transport of the RRE

containing viral mRNAs and the

expression of Gag/Pol and Env proteins.

The inventors have produced an

attenuated HIV by disabling Rev/RRE,

by point mutations, and inserting in its

place the novel murine NCTE of the

invention. The resultant HIV is

attenuated between 50 and 200 fold

compared to wild type HIV. Claimed at

the novel NCTE, recombinant

retroviruses comprising the NCTE and

vaccines.

Dated: October 6, 2000.

Jack Spiegel,

Director, Division of Technology,

Development and Transfer, Office of

Technology Transfer, National Institutes of

Health.

[FR Doc. 00–27358 Filed 10–24–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Consensus Development Conference

on Adjuvant Therapy for Breast Cancer

Notice is hereby given of the National

Institutes of Health (NIH) Consensus

Development Conference on ‘‘Adjuvant

Therapy for Breast Cancer,’’ which will

be held November 1–3, 2000, in the

NIH’s Natcher Conference Center, 9000

Rockville Pike, Bethesda, Maryland

20892. The conference begins at 8:00 am

on November 1 and 2, and at 9:00 am

on November 3 and is open to the

public.

Each year, more than 180,000 women

in the United States are diagnosed with

breast cancer, the most common type of

non-skin cancer among women in this

country. Through continuing research

into new treatment methods, women

with breast cancer now have more

effective treatment options than ever

before. Studies have shown that

adjuvant therapy—treatment to kill

cancer cells that may have begun to

spread, or metastasize, from the breast

tumor—given in addition to surgery or

other primary therapies increases a

woman’s chance of long-term survival.

Two types of systemic adjuvant

therapy, either alone or in combination,

are used for breast cancer. Adjuvant

chemotherapy involves a combination

of anticancer drugs. Adjuvant hormone

therapy deprives cancer cells of the

female hormone estrogen, which some

breast cancer cells need to grow. In

addition to these systemic therapies,

radiation therapy is sometimes used as

a local adjuvant treatment to help

destroy breast cancer cells that have

spread to nearby tissues.

The rapid pace of discovery in this

area continues to broaden the

knowledge base from which informed

treatment decisions can be made. The

purpose of this conference is to clarify,

for clinicians, patients, and the general

public, various issues regarding the use

of adjuvant therapy for breast cancer.

After 11⁄2 days of presentations and

audience discussion of the latest

adjuvant therapy research, an

independent, non-Federal consensus

development panel will weigh the

scientific evidence and draft a statement

that will be presented to the conference

audience on the third day. The

consensus development panel’s

statement will address the following key

questions:

Which factors should be used to select

systemic adjuvant therapy? 

For which patients should adjuvant

hormonal therapy be recommended? 

For which patients should adjuvant

chemotherapy be recommended?

Which agents should be used and at

what dose or schedule? 

For which patients should

postmastectomy radiotherapy be

recommended? 

How do side effects and quality-of-life

issues factor into individual decisionmaking about adjuvant therapy? 

What are promising new research

directions for adjuvant therapy? 

On the final day of the conference, the

panel’s draft statement will be read in

public, at which time members of the

public are invited to offer comments on

the draft.

The primary sponsors of this meeting

are the National Cancer Institute and the

NIH Office of Medical Applications of

Research. Cosponsors include the

National Institute of Nursing Research

and the NIH Office of Research on

Women’s Health.

This is the 114th Consensus

Development Conference held by the

NIH in the 23-year history of the

Consensus Development Program.

Advance information about the

conference and conference registration

materials may be obtained from

Prospect Associates of Silver Spring,

Maryland, by calling (301) 592–3320 or

by sending e-mail to

breastcancer@prospectassoc.com.

Prospect Associates’ address is 10720

Columbia Pike, Suite 500, Silver Spring,

Maryland 20901–4437. A conference

agenda and registration information is

also available on the NIH Consensus

Program Web site at http://

consensus.nih.gov.

Dated: October 13, 2000.

Ruth L. Kirschstein,

Principal Deputy Director, National Institutes

of Health.

[FR Doc. 00–27357 Filed 10–24–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the meeting of the

National Cancer Institute Board of

Scientific Advisors.

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(6) and 552b(c)(9)(B), Title 5

U.S.C. The discussions could reveal

information of a personal nature where

disclosure would constitute a clearly

unwarranted invasion of personal

privacy and the premature disclosure of

discussions related to personnel and

confidential administrative information

would be likely to significantly frustrate

the subsequent implementation of

recommendations.

Name of Committee: National Cancer

Institute Board of Scientific Advisors.

Date: November 16–17, 2000.

Open: November 16, 8:30 am to 5 pm;

November 17, 8:30 am to 2 pm.

Agenda: Report of the Director, NCI;

Ongoing and New Business, Status Reports,

Budget Presentation, Reports of Special

Initiatives, and RFA/RFP Concept Reviews.

Closed: November 16, 5 pm to 6 pm.

Agenda: To review and evaluate personnel

and programmatic issues.

Place: National Cancer Institute, 9000

Rockville Pike, Building 31, C Wing, 6 Floor,

Conference Room 10, Bethesda, MD 20892.

Contact Person: Paulette S. Gray, Ph.D.,

Executive Secretary, Deputy Director,

Division of Extramural Activities, National

Cancer Institute, National Institutes of

Health, 6116 Executive Boulevard, Room

8141, Bethesda, MD 20892, (301) 496–4218.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Federal Register / Vol. 65, No. 207 / Wednesday, October 25, 2000 / Notices 63877

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: Octoberr 16, 2000.

LaVerne Y. Stingfield,

Director, Office of Federal Advisory

Committee Policy, National Institutes of

Health.

[FR Doc. 00–27350 Filed 10–24–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Complementary

and Alternative Medicine; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Center for

Complementary and Alternative Medicine

Special Emphasis Panel, NCCAM–H07 SEP.

Date: November 9, 2000.

Time: 8:00 AM to 5:00 PM.

Agenda: To review and evaluate grant

applications.

Place: Neuroscience Center, National

Institutes of Health, 6001 Executive Blvd.,

Bethesda, MD 20892.

Contact Person: Cecelia Maryland, Grants

Technical Assistant, National Center for

Complementary and Alternative Medicine,

National Institutes of Health, Building 31,

Room 5B50, Bethesda, MD 20892, (301) 480–

2419.

Dated: October 16, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–27353 Filed 10–24–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Human Genome Research

Institute; Notice of Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

Board of Scientific Counselors, National

Human Genome Research Institute.

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public as indicated below in accordance

with the provisions set forth in section

552b(c)(6), Title 5 U.S.C., as amended

for the review, discussion, and

evaluation of individual intramural

programs and projects conducted by the

National Human Genome Research

Institute, including consideration of

personnel qualifications and

performance, and the competence of

individual investigators, the disclosure

of which would constitute a clearly

unwarranted invasion of personal

privacy.

Name of Committee: Board of Scientific

Counselors, National Human Genome

Research Institute.

Date: November 13–15, 2000.

Open: November 13, 2000, 6:00 p.m. to

6:30 p.m.

Agenda: To discuss program documents.

Place: Airlie House, 6802 Airlie Road,

Warrenton, VA 20187.

Closed: November 14, 2000, 8:30 a.m. to

Adjournment on November 15, 2000.

Agenda: To review and evaluate personal

qualifications and performance, and

competence of individual investigators.

Place: Airlie House, 6809 Airlie Road,

Warrenton, VA 20187.

Contact Person: Claire Rodgaard, Assistant

to the Scientific Director, Division of

Intramural Research, Office of the Director,

National Human Genome Research Institute,

45 Convent Drive, Building 49, Room 4A06,

Bethesda, MD 20892, 301 435–5802.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.172, Human Genome

Research, National Institutes of Health, HHS)

Dated: October 16, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–27354 Filed 10–24–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and

Musculoskeletal and Skin Diseases;

Notice of Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Arthritis and Musculoskeletal and Skin

Diseases Special Emphasis Panel.

Date: November 8, 2000.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant

applications.

Place: Bethesda Marriot, 5151 Pooks Hill

Road, Bethesda, MD 20814.

Contact Person: Aftab A. Ansari, PhD,

National Institutes of Health, NIAMS,

Natcher Building, 45 Center Drive, Room

5AS25N, Bethesda MD 20892, 301–594–

4952.

Name of Committee: National Institute of

Arthritis and Musculoskeletal and Skin

Diseases Special Emphasis Panel.

Date: November 9–10, 2000.

Time: 8:30 a.m. to 3 p.m.

Agenda: To review and evaluate grant

applications.

Place: Bethesda Marriot, 5151 Pooks Hill

Road, Bethesda, MD 20814.

Contact Person: Aftab A. Ansari, Phd,

National Institutes of Health, NIAMS,

Natcher Building, 45 Center Drive, Room

5AS25N, Bethesda, MD 20892, 301–594–

4952.

Name of Committee: National Institute of

Arthritis and Musculoskeletal and Skin

Diseases Special Emphasis Panel.

Date: November 30, 2000.

Time: 10:30 a.m. to 4 p.m.

Agenda: To review and evaluate grant

applications.

Place: Hyatt Regency, One Metro Center,

Bethesda, MD 20814.

Contact Person: Aftab A. Ansari, Phd,

National Institutes of Health, NIAMS,

Natcher Building, 45 Center Drive, Room

5AS25N, Bethesda, MD 20892, 301–594–

4952.

Name of Committee: National Institute of

Arthritis and Musculoskeletal and Skin

Diseases Special Emphasis Panel.

Date: December 13, 2000.